Navigation Links
The Debiopharm Life Sciences Award Goes to Dr Nusser for his Outstanding Research in Neuroscience

LAUSANNE, Switzerland, August 30 /PRNewswire/ -- Debiopharm Group (Debiopharm), a global independent biopharmaceutical development specialist in oncology and serious medical conditions, today presented the 'Debiopharm Life Sciences Award' to Hungarian scientist Dr Zoltan Nusser for his outstanding research in both fundamental and clinical neuroscience. Funded by Debiopharm and organised by the Ecole Polytechnique Federale de Lausanne (EPFL), the ceremony took place during the EPFL Life Science Symposium 2007. Dr Nusser and his institute received CHF 100'000 and an etched crystal tribute commemorating this honour.

"We were impressed with the quality of research conducted by Dr Nusser," said Rolland-Yves Mauvernay, President of Debiopharm Group. "And more importantly, his work could be applied to drugs that would make a difference to the lives of patients."

"The Debiopharm Life Sciences Award 2007 underscores the spectacular progress we have made in understanding the fundamental mechanisms involved in sensorial perception," added Patrick Aebischer, President of EPFL.

Dr Nusser's work, at the Hungarian Academy of Sciences of Budapest, focuses on understanding the sub cellular organisation and function of synapses in the central nervous system (CNS) and their involvement in neuronal network activities underlying sensory perception. The application of his research could lead to the development of new treatments for patients suffering from CNS diseases. He has received various prizes and has published his research in leading publications including Nature, Neuron and Proceedings of the National Academy of Sciences (PNAS).

About the Debiopharm Life Sciences Award

The Award was set up to mentor and motivate young innovative European researchers in the field of life sciences. Criteria for applications include novelty and originality of the work, as well as its importance and significance in connection with targeted therapeutic fields.

Debiopharm also presents the 'Debiopharm-CCRF China Award' in China; and the 'JCA-Mauvernay Award' in Japan.

About Debiopharm Group

Debiopharm Group is a global biopharmaceutical development specialist that in-licenses promising biologics and small molecule drug candidates. Debiopharm develops its products for global registration and maximum commercial potential for out-licensing to pharmaceutical partners for sales and marketing. Debiopharm independently funds the worldwide development of all of its products while providing expertise in pre-clinical and clinical trials, manufacturing, drug delivery and formulation, and regulatory affairs.

Founded in 1979 and headquartered in Lausanne, Switzerland, Debiopharm has developed three products with global combined sales in excess of $2.6 billion in 2006.

For more information on Debiopharm Group, please visit:

Debiopharm S.A. Contacts

Kim Bill

VP, Business Development &


Tel.: +41-(0)21-321-01-11

Fax: +41-(0)21-321-01-69

Additional Media Contacts

In London


Brian Hudspith

Tel: +44-(0)20-7379-5151

In New York

Russo Partners, LLC

Wendy Lau

Tel: +1-212-845-4272

Fax: +1-212-845-4260

SOURCE The Debiopharm Group
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Automation of the Eppendorf Perfectprep BAC 96 DNA Kit on the Caliper Life Sciences Sciclone ALH 3000
2. Perscitus Biosciences secures $250K Commerce loan
3. Wisconsin biosciences rise to the challenge
4. Wisconsin professors elected to National Academy of Sciences
5. Quintessence Biosciences advances cancer drug
6. Quintessence Biosciences names new president
7. InvivoSciences receives NIH grant for heart technology
8. Caden Biosciences may signal critical mass
9. Wisconsin start up Primorigen Biosciences corrals out-of-state investment
10. QBI Life Sciences snags $130,000 NIH grant
11. WARF signs licensing pact with BD Biosciences
Post Your Comments:
(Date:11/24/2015)... -- Cepheid (NASDAQ: CPHD ) today announced that ... and invited investors to participate via webcast. ... 1, 2015 at 11.00 a.m. Eastern Time --> ... 1, 2015 at 11.00 a.m. Eastern Time --> ... NY      Tuesday, December 1, 2015 at 11.00 ...
(Date:11/24/2015)... /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ:  AEZS) (TSX: AEZ) (the ... the Toronto Stock Exchange, confirms that as of the ... developments that would cause the recent movements in the ... --> About Aeterna Zentaris Inc. ... Aeterna Zentaris is a specialty biopharmaceutical company engaged in ...
(Date:11/24/2015)... 24, 2015 SHPG ) announced today that ... Piper Jaffray 27 th Annual Healthcare Conference in ... at 8:30 a.m. EST (1:30 p.m. GMT). --> SHPG ... will participate in the Piper Jaffray 27 th Annual Healthcare ... Tuesday, December 1, 2015, at 8:30 a.m. EST (1:30 p.m. GMT). ...
(Date:11/24/2015)... ... November 24, 2015 , ... In harsh industrial ... points for in-line sensors can represent a weak spot where leaking process media ... of retractable sensor housings , which are designed to tolerate extreme process conditions. ...
Breaking Biology Technology:
(Date:11/19/2015)... , Nov. 19, 2015  Although some 350 ... is dominated by a few companies, according to Kalorama ... own 51% of the market share of the 6.1 ... The World Market for Molecular Diagnostic s . ... "The market is still controlled by one company and ...
(Date:11/17/2015)... 2015  Vigilant Solutions announces today that Mr. ... Directors. --> --> ... the partnership at TPG Capital, one of the largest ... Billion in revenue.  He founded and led TPG,s Operating ... companies, from 1997 to 2013.  In his first role, ...
(Date:11/12/2015)...   Growing need for low-cost, easy to ... paving the way for use of biochemical sensors ... in clinical, agricultural, environmental, food and defense applications. ... medical applications, however, their adoption is increasing in ... emphasis on improving product quality and growing need ...
Breaking Biology News(10 mins):